Primary Biliary Cholangitis Pipeline Summary

DelveInsight’s, “Primary Biliary Cholangitis Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis (PBC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Primary Biliary Cholangitis Understanding

Primary Biliary Cholangitis Overview

Primary Biliary Cholangitis (PBC) is a chronic, progressive autoimmune disease that primarily affects the bile ducts in the liver. It leads to inflammation and gradual destruction of the small bile ducts, causing bile to accumulate in the liver (cholestasis). Over time, this can result in liver damage, fibrosis, and eventually cirrhosis. Although the exact cause of PBC remains unclear, it predominantly affects middle-aged women and is considered an autoimmune disorder. Genetic and environmental factors, such as infections or toxic exposures, may contribute to its onset.
Early stages of PBC may be asymptomatic, but as the disease progresses, common symptoms include persistent fatigue, pruritus (itching), and dry eyes or mouth. Advanced stages can lead to jaundice (yellowing of the skin and eyes), dark urine, pale stools, and swelling in the abdomen or legs due to fluid retention. Complications include vitamin deficiencies, osteoporosis, and an increased risk of liver failure or hepatocellular carcinoma.

The exact cause of PBC is unknown, but it is thought to result from an autoimmune reaction where the body's immune system mistakenly attacks the bile ducts. A genetic predisposition may play a role, as PBC is more common in individuals with a family history of autoimmune diseases. Environmental triggers, such as infections or toxins, might also contribute to initiating the immune response.
PBC is typically diagnosed through a combination of blood tests, imaging studies, and sometimes liver biopsy. Elevated levels of alkaline phosphatase (ALP) and other liver enzymes suggest bile duct dysfunction. The presence of antimitochondrial antibodies (AMA) in the blood is a key diagnostic marker, present in over 90% of cases. Imaging tests like ultrasound or MRI rule out other conditions affecting the bile ducts, and a liver biopsy may confirm the diagnosis and assess disease severity.
There is no cure for PBC, but treatments aim to slow disease progression, alleviate symptoms, and manage complications. Ursodeoxycholic acid (UDCA) is the first-line medication that improves bile flow and liver function. Obeticholic acid (OCA) may be prescribed for patients unresponsive to UDCA. Symptomatic treatments include antihistamines for itching and supplements for vitamin deficiencies. Advanced cases may require liver transplantation, which is curative. Lifestyle modifications, such as avoiding alcohol and maintaining a balanced diet, are also recommended to support liver health.

"Primary Biliary Cholangitis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Biliary Cholangitis (PBC) pipeline landscape is provided which includes the disease overview and Primary Biliary Cholangitis (PBC) treatment guidelines. The assessment part of the report embraces, in depth Primary Biliary Cholangitis (PBC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Biliary Cholangitis (PBC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Primary Biliary Cholangitis Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Primary Biliary Cholangitis (PBC) R&D. The therapies under development are focused on novel approaches to treat/improve Primary Biliary Cholangitis (PBC).

Primary Biliary Cholangitis Emerging Drugs Analysis

This segment of the Primary Biliary Cholangitis (PBC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Biliary Cholangitis Emerging Drugs

Saroglitazar Magnesium: Zydus Therapeutics

Saroglitazar is a novel Peroxisome Proliferator-Activated Receptor (PPAR) α/γ agonist, currently under investigation as a treatment for patients with PBC. Its distinct biological profile targets both bile acid toxicity and liver inflammation. The US FDA has granted ODD and FTD to saroglitazar Mg for PBC. The US FDA has granted it Priority Review with a target action date of November 27, 2026, for adults who are intolerant to or inadequately respond to standard UDCA therapy. The NDA is supported by the EPICS-III trial Phase III results, a randomized, double-blind, placebo-controlled study evaluating saroglitazar in adult patients with PBC who had an inadequate response to or intolerance of UDCA.

Setanaxib: Calliditas Therapeutics

Setanaxib (GKT831) is an investigational, first-in-class oral NADPH oxidase (NOX) 1/4 inhibitor being developed for the treatment of Primary Biliary Cholangitis, particularly in patients with an inadequate response or intolerance to standard therapy. By selectively inhibiting NOX1 and NOX4 enzymes, Setanaxib aims to reduce oxidative stress, inflammation, and fibrogenesis—key mechanisms involved in the progression of PBC. Clinical studies have demonstrated improvements in biomarkers associated with cholestasis and liver injury, including reductions in gamma-glutamyl transferase (GGT), with an acceptable safety and tolerability profile. Setanaxib has also shown potential antifibrotic effects, making it a promising disease-modifying therapy for PBC. It is currently being evaluated in Phase II clinical development for PBC, with ongoing research focused on confirming its efficacy in slowing disease progression and improving long-term liver outcomes.

DF-5112: Dragonfly Therapeutics

DF-5112 is an investigational monoclonal antibody targeting C-C chemokine receptor 6 (CCR6), being developed by Dragonfly Therapeutics for the treatment of immune-mediated diseases, including Primary Biliary Cholangitis. By antagonizing CCR6, DF-5112 is designed to inhibit the migration and activation of pathogenic Th17 cells and other CCR6-expressing immune cells implicated in chronic inflammation and autoimmune-mediated bile duct injury. This targeted immunomodulatory approach aims to reduce hepatic inflammation while potentially slowing disease progression in patients with PBC who have an inadequate response to standard therapies. As of 2026, DF-5112 is in Phase I clinical development, with ongoing studies evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary biological activity.

Further product details are provided in the report……..

Primary Biliary Cholangitis Drug Therapeutic Assessment

This segment of the report provides insights about the different Primary Biliary Cholangitis (PBC) drugs segregated based on following parameters that define the scope of the report, such as:

Major Primary Biliary Cholangitis Players in Primary Biliary Cholangitis

There are approx. 20+ key companies which are developing the therapies for Primary Biliary Cholangitis (PBC). The companies which have their Primary Biliary Cholangitis (PBC) drug candidates in the most advanced stage, i.e. Registration include, Zydus Therapeutics.

Primary Biliary Cholangitis Clinical Trial Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Primary Biliary Cholangitis Drug Route of Administration

Primary Biliary Cholangitis (PBC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Primary Biliary Cholangitis Product Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Primary Biliary Cholangitis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Biliary Cholangitis Clinical Trial Activities

The Primary Biliary Cholangitis Pipeline report provides insights into different Primary Biliary Cholangitis Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Primary Biliary Cholangitis (PBC) therapeutic drugs key players involved in developing key drugs.

Primary Biliary Cholangitis Pipeline Development Activities

The Primary Biliary Cholangitis Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Biliary Cholangitis (PBC) drugs.

Primary Biliary Cholangitis Report Insights

Primary Biliary Cholangitis (PBC) Pipeline Analysis
Primary Biliary Cholangitis Therapeutic Assessment
Primary Biliary Cholangitis Unmet Needs
Impact of Primary Biliary Cholangitis Drugs

Primary Biliary Cholangitis (PBC) Report Assessment

Primary Biliary Cholangitis Pipeline Product Profiles
Primary Biliary Cholangitis Therapeutic Assessment
Primary Biliary Cholangitis Pipeline Assessment
Primary Biliary CholangitisInactive drugs assessment
Primary Biliary Cholangitis Market Unmet Needs

Key Questions Answered in the Primary Biliary Cholangitis Pipeline Report

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Primary Biliary Cholangitis (PBC) drugs?
How many Primary Biliary Cholangitis (PBC) drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Biliary Cholangitis (PBC)?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary Biliary Cholangitis (PBC) therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Primary Biliary Cholangitis (PBC) and their status?
What are the key designations that have been granted to the emerging drugs?